Wanbury Limited

NSE WANBURY.NS

Wanbury Limited EBITDA for the year ending March 31, 2024: USD 11.82 M

Wanbury Limited EBITDA is USD 11.82 M for the year ending March 31, 2024, a 313.38% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Wanbury Limited EBITDA for the year ending March 31, 2023 was USD 2.86 M, a -80.83% change year over year.
Wanbury Limited EBITDA for the year ending March 31, 2022 was USD 14.91 M, a 434.45% change year over year.
Wanbury Limited EBITDA for the year ending March 31, 2021 was USD 2.79 M, a -80.40% change year over year.
Wanbury Limited EBITDA for the year ending March 31, 2020 was USD 14.23 M, a 297.60% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NSE: WANBURY.NS

Wanbury Limited

CEO	Mr. Pradeep Patni
IPO Date	Jan. 29, 2007
Location	India
Headquarters	BSEL Tech Park, B-Wing
Employees	1,491
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Key trends

Past 5 years